Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Braeburn to market Titan Pharma’s Probuphine in North America; rights may be returned; terminated

Executive Summary

Neurology company Titan Pharmaceuticals Inc. has licensed start-up Braeburn Pharmaceuticals SPRL exclusive US (including Puerto Rico) and Canadian rights to Probuphine (buprenorphine implant), which is awaiting approval for opioid addiction. The term of the transaction is 15 years, or when the last patent expires, whichever is later.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Medical Devices
    • Implantable Devices
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies